Isorhamnetin has the potential to influence ovarian cancer cell proliferation and apoptosis by targeting intracellular PI3K/Akt signaling pathway promoters of the cell cycle (cyclins) and apoptosis (Bax, Bcl, and cytochrome) (52, 77). This evidence concerns the gene AKT1 and ovarian carcinoma.